Assessment of Artesunate/Mefloquine in the Peruvian Amazon
Status:
Completed
Trial end date:
2016-04-13
Target enrollment:
Participant gender:
Summary
There is growing evidence of the emergence of P. falciparum resistance to artesunate (a
derivative of artemisin) in Southeast Asia. The emergence and spread of resistant strains to
artemisinin would represent an alarming threat to the success of the antimalarial combination
therapy in the region. The delayed clearance of parasitemia for more than 24 hours has been
taken as an early sign of resistance, a phenomenon seen at the Thai-Cambodia border.
The purpose of this research study, is to assess the in vitro and in vivo efficacy of
combinated artesunate/mefloquine therapy to treatment of uncomplicated Plasmodium falciparum
malaria in the Peruvian Amazon through the analysis of the rate of clearance of parasitemia
and other important outcomes.
Phase:
Phase 4
Details
Lead Sponsor:
Instituto Nacional de Salud. Peru
Collaborators:
Naval Medical Research Unit No 6 U.S. Naval Medical Research Unit No.6 (NAMRU-6)